Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sacituzumab Tirumotecan HER2 Positive Breast Carcinoma	Fudan University	P2	CCC (53)
Sacituzumab Tirumotecan Inetetamab	Fudan University	P2	CCC (53)
Sacituzumab Tirumotecan Metastatic Breast Cancer ( HER2 Negative)	Fudan University	P2	CCC (53)
Sacituzumab Tirumotecan Myelosuppression, Non-Human Animal	The First Affiliated Hospital of Xiamen University	P2	CCC (53)
Sacituzumab Tirumotecan Prostate Neuroendocrine Neoplasm	Virginia Commonwealth University	P2	CCC (53)
Sacituzumab Tirumotecan PD-L1 Positive	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Sacituzumab Tirumotecan Potentially Resectable	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (53)
Sacituzumab Tirumotecan Prostate Adenocarcinoma With Neuroendocrine Differentiation	Tianjin Medical University Second Hospital	P2	CCC (53)
Sacituzumab Tirumotecan Prostate Adenocarcinoma	Tianjin Medical University Second Hospital	P2	CCC (53)
Sacituzumab Tirumotecan Castration-Resistant Prostate Carcinoma	Tianjin Medical University Second Hospital	P2	CCC (53)
Sacituzumab Tirumotecan SKB264	Fudan University	P2	CCC (53)
Sacituzumab Tirumotecan Triple-negative Breast Cancer and HR+/HER2- BC	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P2	CCC (53)
Shr-A2009 Breast Neoplasm	Fudan University	P2	CCC (53)
Shr-A2009 Hormone Receptor Positive Tumor	Fudan University	P2	CCC (53)
T-Dxd Estrogen-Receptor Positive Breast Cancer	Guangzhou Women and Children's Medical Center	P2	CCC (53)
Tisotumab Vedotin Exocrine Pancreatic Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Trastuzumab Deruxtecan Advanced or Metastatic Solid Tumour	Jules Bordet Institute	P2	CCC (53)
Trastuzumab Deruxtecan Alopecia	Jules Bordet Institute	P2	CCC (53)
Trastuzumab Deruxtecan Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Deruxtecan Antibody-Drug Conjugate	Jules Bordet Institute	P2	CCC (53)
Trastuzumab Deruxtecan Brain Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Trastuzumab Deruxtecan Chemotherapy-Induced Alopecia	Dana-Farber Cancer Institute	P2	CCC (53)
Trastuzumab Deruxtecan CRPC	Washington D.C. Veterans Affairs Medical Center	P2	CCC (53)
Trastuzumab Deruxtecan Breast Adenocarcinoma	Filipa Lynce, MD	P2	CCC (53)
Trastuzumab Deruxtecan Hormone Receptor Negative Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)

Showing 451 to 475 of 1,027 assets

PreviousPage 19 of 42Next